New promising molecular targets in head and neck squamous cell carcinoma

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 235-242

  Bauman, Julie E ^a   Michel, Loren S ^b   Chung, Christine H ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b USA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA damage repair; EGFR; HNSCC; HPV; hypoxia; MET; NOTCH1; PIK3CA; TP53

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; AFATINIB; ANTINEOPLASTIC AGENT; BORTEZOMIB; CETUXIMAB; CHALCONE DERIVATIVE; DACOMITINIB; E 7050; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; LAPATINIB; MK 2206; NIMORAZOLE; NIMOTUZUMAB; NUTLIN 3; OLAPARIB; PANITUMUMAB; PF 3084014; PRIMA 1; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VENDETANIB; ZALUTUMUMAB;

DNA DAMAGE; DNA REPAIR; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY; MUTAGENICITY; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TOBACCO; TUMOR SUPPRESSOR GENE; WART VIRUS;

ALCOHOL DRINKING; ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, NOTCH1; SMOKING; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859813676     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283517920     Document Type: Review

References (93)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150. (Pubitemid 46655601)
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098. (Pubitemid 37464533)
3. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
5. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. (Pubitemid 350005152)
6. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332:712-717.
7. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-720. (Pubitemid 30365531)
8. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956. (Pubitemid 46740304)
9. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630-5636. (Pubitemid 46631302)
10. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269. (Pubitemid 351480538)
11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35.
12. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28:4142-4148.
13. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011; 100:49-55.
14. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22:1071-1077.
15. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26:612-619. (Pubitemid 351264356)
16. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-4301.
17. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1992-1998.
18. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2009; 94:30-35.
19. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-350. (Pubitemid 37328947)
20. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324:17-27. (Pubitemid 38737395)
21. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-475. (Pubitemid 40270113)
22. Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505. (Pubitemid 23335075)
23. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56:4620-4624. (Pubitemid 26338060)
24. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101:412-423.
25. Baleja JD, Cherry JJ, Liu Z, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006; 72:49-59. (Pubitemid 44291470)
26. Ro HS, Koh BH, Jung SO, et al. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6, E6AP, and p53. Proteomics 2006; 6:2108-2111.
27. Anchoori RK, Khan SR, Sueblinvong T, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One 2011; 6:e23888.
28. Chung CH, Aulino J, Muldowney NJ, et al., Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010; 21:864-870.
29. Argiris A, Duffy AG, Kummar S, et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 2011; 17:5755-5764.
30. Wansom D, Light E, Worden F, et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1267-1273.
31. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135:1137-1146.
32. Harris M, Wang XG, Jiang Z, et al. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011; 3:9.
33. Wu A, Zeng Q, Kang TH, et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 18:304-312.
34. Wick DA, Webb JR. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 2011; 29:7857-7866.
35. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-130. (Pubitemid 36331971)
36. Grandis J, Melhem M, Gooding W, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832. (Pubitemid 28280548)
37. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176. (Pubitemid 46622295)
38. Pectasides E, Rampias T, Kountourakis P, et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17:2947-2954.
39. Chung CH, Zhang Q, Hammond EM, et al. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2011; 81:331-338.
40. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
41. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89:2965-2969.
42. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-5073. (Pubitemid 44453332)
43. Tinhofer I, Klinghammer K, Weichert W, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011; 17:5197-5204.
44. Chau NG, Perez-Ordonez B, Zhang K, et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 2011; 3:11.
45. Yang L, Jiang H, Shi B, et al. Identification and characterization of Ch806 mimotopes. Cancer Immunol Immunother 2010; 59:1481-1487.
46. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007; 104:4071-4076. (Pubitemid 47181580)
47. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-4729.
48. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-3956. (Pubitemid 351913636)
49. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043. (Pubitemid 46799492)
50. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-1356.
51. Galer CE, Corey CL, Wang Z, et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011; 33:189-198.
52. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935-5944.
53. Siu L, Hotte S, Laurie S, et al., Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2011; 29(Suppl):Abstract 5561.
54. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112:2088-2100. (Pubitemid 351574086)
55. Basu D, Nguyen TT, Montone KT, et al. Evidence for mesenchymal-like subpopulations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene 2010; 29:4170-4182.
56. Basu D, Montone KT, Wang LP, et al. Detecting and targeting mesenchymallike subpopulations within squamous cell carcinomas. Cell Cycle 2011; 10:2008-2016
57. Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226:2378-2390.
58. Wheeler DL, Iida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009; 8:696-703.
59. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12:3657-3660. (Pubitemid 44000247)
60. Knowles LM, Stabile LP, Egloff AM, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009; 15:3740-3750.
61. Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021-3031.
62. Ghadjar P, Blank-Liss W, Simcock M, et al. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis 2009; 26:809-815.
63. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154-1157.
64. Stransky N, Egloff AM, Tward AD, et al., The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-1160.
65. Xu H, Stabile LP, Gubish CT, et al. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011; 17:4425-4438.
66. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606-619. (Pubitemid 44100518)
67. Kurasawa Y, Shiiba M, Nakamura M, et al. PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep 2008; 19:1429-1434.
68. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35.
69. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10:558-565.
70. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357:2552-2561. (Pubitemid 350294222)
71. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107:246-251.
72. Muller PA, Caswell PT, Doyle B, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139:1327-1341.
73. Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010; 396:85-89.
74. Roh JL, Kang SK, Minn I, et al. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 2011; 47:8-15.
75. Struhl G, Adachi A. Nuclear access and action of notch in vivo. Cell 1998; 93:649-660. (Pubitemid 28240725)
76. Demarest RM, Dahmane N, Capobianco AJ. Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood 2011; 117:2901-2909.
77. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101-105.
78. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011; 473:230-233.
79. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33:416-421. (Pubitemid 36278861)
80. Palom Y, Suresh Kumar G, Tang LQ, et al. Relative toxicities of DNA crosslinks and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chem Res Toxicol 2002; 15:1398-1406. (Pubitemid 35364901)
81. Clingen PH, Wu JY, Miller J, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008; 76:19-27.
82. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001; 2:483-490. (Pubitemid 33586303)
83. Al-Minawi AZ, Lee YF, Hakansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 2009; 37:6400-6413.
84. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008; 99:167-172. (Pubitemid 351920246)
85. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatinbased induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13:3855-3859. (Pubitemid 47037591)
86. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and nonsmall-cell lung cancer. N Engl J Med 2007; 356:2538-2540; author reply 2540-1.
87. Hao D, Lau HY, Eliasziw M, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck 2011. [Epub ahead of print]
88. Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res 2011; 17:5513-5522.
89. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25:4066-4074. (Pubitemid 47492951)
90. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011; 100:22-32.
91. Hicks KO, Siim BG, Jaiswal JK, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010; 16:4946-4957.
92. Byers LA, Holsinger FC, Kies MS, et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010; 9:1755-1763.
93. Toustrup K, Sorensen BS, Lassen P, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012; 102:122-129.